HC Wainwright Maintains Buy Rating on Evotec, Lowers Price Target to $7.00

Evotec (EVO) stock maintains a "Buy" rating from HC Wainwright & Co. analyst Douglas Tsao, but the price target is lowered from $8.00 to $7.00 USD, a 12.50% decrease. The analyst remains confident in the company's potential despite the adjustment. Evotec offers drug discovery partnership services to pharmaceutical and biotechnology companies, academic institutions, and non-profit organizations.

Evotec SE (EVO) stock has maintained a "Buy" rating from HC Wainwright & Co. analyst Douglas Tsao, despite a significant reduction in the price target from $8.00 to $7.00 USD. This 12.50% decrease in the price target reflects recent earnings performance and guidance for the full year [2].

Evotec SE, a Hamburg-based company specializing in drug discovery partnership services, reported its first-half 2025 results, showing a quarterly adjusted loss of 12 cents per share, an improvement from the same period last year when the company reported an EPS of -27 cents. Revenue decreased by 6% to €171.24 million compared to the prior year, falling short of analyst expectations of €205.14 million [3].

The company's quarterly loss amounted to €43.48 million, while shares experienced a 9.3% drop during the quarter and an 8.4% decline year-to-date. Analysts had expected a loss of 13 cents per share, with estimates ranging from -18 cents to -8 cents per share. The mean earnings estimate of analysts had risen by about 3.7% in the last three months, with no revisions in the last 30 days [3].

HC Wainwright & Co. maintained its "buy" rating on Evotec SE, but lowered its price target to $7.00 from $12.00, reflecting the company's recent earnings performance and guidance for the full year. The new price target is about 45.6% above the last closing price of $3.81 [2].

Evotec's first-half 2025 results were in line with expectations, with adjusted EBITDA of -€1.9 million, compared to -€0.5 million in the same period last year. The company expects full-year 2025 group revenues to range between €760 million and €800 million, with R&D expenditures ranging from €40 million to €50 million. Adjusted group EBITDA is expected to reach between €30 million and €50 million [2].

The current average analyst rating on the shares is "hold," with 2 "strong buy" or "buy" recommendations, no "hold" recommendations, and 1 "sell" or "strong sell" recommendation. Wall Street's median 12-month price target for Evotec SE is $7.00, about 45.6% above its last closing price of $3.81 [3].

Despite the recent earnings performance and guidance, the "buy" rating from HC Wainwright & Co. suggests that the market still sees potential in Evotec's long-term prospects. Investors should closely monitor the company's progress and earnings releases to make informed decisions.

References:
[1] https://www.tradingview.com/news/reuters.com,2025:newsml_L8N3U303U:0-evotec-se-expected-to-post-a-loss-of-13-cents-a-share-earnings-preview/
[2] https://www.ainvest.com/news/evotec-hc-wainwright-maintains-buy-rating-pt-7-2508/
[3] https://www.tradingview.com/news/reuters.com,2025:newsml_L8N3U50DX:0-evotec-se-reports-results-for-the-quarter-ended-june-30-earnings-summary/